Deals In Depth: October 2011
Executive Summary
October’s dealmaking highlights: Biogen received exclusive global rights to Portola’s autoimmune and anti-inflammatory Syk inhibitors in an alliance worth $554 million. Investment firms took public CRO Pharmaceutical Product Development private for $33.25 per share, or a total of $3.9 billion, including debt. Regeneron’s $391 million notes sale propelled the debt category to claim almost half of the $826 million biopharma financing figure. Meantime device companies raised $206 million, mainly from Zeltiq’s $93 million IPO.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.